CoChat
Sign Up
Cited by 20RNA Interference and Gene Deliveryinterferon and immune responsesVirus-based gene therapy research

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The potential of RNA interference-based therapies for viral infections

Open access
Huang, Diana D.·2008·Current HIV/AIDS Reports
DOI 10.1007/s11904-008-0006-4PMC PMC7088822
Open this paper in CoChat — free accountOpen PDF

Abstract

RNA interference (RNAi) is a natural mechanism in cells that suppresses or silences the expression of aberrant or foreign genes. This activity is being developed as a potential antiviral therapeutic strategy. Studies in vitro, and some in vivo, appear to show the feasibility of using RNAi to treat virus infection. Therapeutic use of RNAi seems to be promising when directed against viruses that cause localized acute infections in accessible target cells. Therapeutic strategies using RNAi against viruses that cause chronic infections, such as HIV, hepatitis B virus, or hepatitis C virus, are more difficult to design, but studies have begun to address identifiable problems. Two clinical trials using RNAi have recently been initiated--one phase II trial against respiratory syncytial virus and a phase I trial against HIV. It will be of much interest to see whether nucleic acid therapies can offer another route to treating viral infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11904-008-0006-4

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • RNAi has been employed preclinically and clinically in treatment of several types of disease including viruses and cancer, but has not been employed in stroke therapy.

    “RNAi has been employed preclinically and clinically in treatment of several types of disease including viruses and cancer [26, 27], but has not been employed in stroke therapy.”

    From MicroRNA‐21 protects neurons from ischemic death (2010) · cites this paper as [26]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 46

  1. Rossi JJ: Interference and inhibition: RNAi mechanisms and therapeutic prospects. Presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia; July 22–25, 2007.
  2. Li M, Li H, Rossi JJ: RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann N Y Acad Sci 2006, 1082:172–179. · DOI
  3. Robbins MA, Li M, Leung I, et al.: Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol 2006, 24:566–571. · DOI
  4. Michienzi A, Castanotto D, Lee N, et al.: RNA-mediated inhibition of HIV in a gene therapy setting. Ann N Y Acad Sci 2003, 1002:63–71. · DOI
  5. Scherer L, Rossi JJ, Weinberg MS: Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther 2007, 14:1057–1064. · DOI
  6. Yeung ML, Bennasser Y, Le SY, Jeang KT: siRNA, miRNA and HIV: promises and challenges. Cell Res 2005, 15:935–946. · DOI
  7. Wilson JF: Gene therapy yields to RNA interference. Ann Intern Med 2005, 143:161–164. · DOI
  8. Amado RG, Mitsuyasu RT, Rosenblatt JD, et al.: Antihuman immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 2004, 15:251–262. · DOI
  9. Levine BL, Humeau LM, Boyer J, et al.: Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 2006, 103:17372–17377. · DOI
  10. Tijsterman M, Ketting RF, Plasterk RH: The genetics of RNA silencing. Annu Rev Genet 2002, 36:489–519. · DOI
  11. Leonard JN, Schaffer DV: Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther 2006, 13:532–540. · DOI
  12. Check E: Pioneering HIV treatment would use interference and gene therapy. Nature 2005, 437:601. · DOI
  13. Grimm D, Kay MA: Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 2006, 13:563–575. · DOI
  14. Dykxhoorn DM, Lieberman J: Knocking down disease with siRNAs. Cell 2006, 126:231–235. · DOI
  15. Dykxhoorn DM, Lieberman J: Silencing viral infection. PLoS Med 2006, 3:e242. · DOI
  16. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J: Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6:443–453. · DOI
  17. Zamore PD, Aronin N: siRNAs knock down hepatitis. Nat Med 2003, 9:266–267. · DOI
  18. Boden D, Pusch O, Lee F, et al.: Human immunodeficiency virus type 1 escape from RNA interference. J Virol 2003, 77:11531–11535. · DOI
  19. Das AT, Brummelkamp TR, Westerhout EM, et al.: Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004, 78:2601–2605. · DOI
  20. Westerhout EM, Ooms M, Vink M, et al.: HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res 2005, 33:796–804. · DOI
  21. Wilson JA, Richardson CD: Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J Virol 2005, 79:7050–7058. · DOI
  22. Bitko V, Musiyenko A, Shulyayeva O, Barik S: Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005, 11:50–55. · DOI
  23. Ge Q, Filip L, Bai A, et al.: Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A 2004, 101:8676–8681. · DOI
  24. Tompkins SM, Lo CY, Tumpey TM, Epstein SL: Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A 2004, 101:8682–8686. · DOI
  25. Li BJ, Tang Q, Cheng D, et al.: Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 2005, 11:944–951. · DOI
  26. Kumar P, Lee SK, Shankar P, Manjunath N: A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med 2006, 3:e96. · DOI
  27. Morrissey DV, Blanchard K, Shaw L, et al.: Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005, 41:1349–1356. · DOI
  28. Morrissey DV, Lockridge JA, Shaw L, et al.: Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005, 23:1002–1007. · DOI
  29. Chen CC, Ko TM, Ma HI, et al.: Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther 2007, 14:11–19. · DOI
  30. McCaffrey AP, Nakai H, Pandey K, et al.: Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003, 21:639–644. · DOI
  31. Ying RS, Zhu C, Fan XG, et al.: Hepatitis B virus is inhibited by RNA interference in cell culture and in mice. Antiviral Res 2007, 73:24–30. · DOI
  32. Klein C, Bock CT, Wedemeyer H, et al.: Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003, 125:9–18. · DOI
  33. Merl S, Michaelis C, Jaschke B, et al.: Targeting 2A protease by RNA interference attenuates coxsackieviral cytopathogenicity and promotes survival in highly susceptible mice. Circulation 2005, 111:1583–1592. · DOI
  34. Xiong D, Lee GH, Badorff C, et al.: Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med 2002, 8:872–877. · DOI
  35. Fechner H, Pinkert S, Wang X, et al.: Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor. Gene Ther 2007, 14:960–971. · DOI
  36. Jopling CL, Yi M, Lancaster AM, et al.: Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577–1581. · DOI
  37. Song E, Lee SK, Wang J, et al.: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003, 9:347–351. · DOI
  38. Niu XY, Peng ZL, Duan WQ, et al.: Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer 2006, 16:743–751. · DOI
  39. Yokota T, Iijima S, Kubodera T, et al.: Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C. Biochem Biophys Res Commun 2007, 361:294–300. · DOI
  40. Novina CD, Murray MF, Dykxhoorn DM, et al.: siRNA-directed inhibition of HIV-1 infection. Nat Med 2002, 8:681–686. · DOI
  41. Qin XF, An DS, Chen IS, Baltimore D: Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 2003, 100:183–188. · DOI
  42. Anderson J, Akkina R: HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther 2005, 2:1. · DOI
  43. Bennasser Y, Le SY, Benkirane M, Jeang KT: Evidence that HIV-1 encodes an siRNA and a suppressor of RNA silencing. Immunity 2005, 22:607–619. · DOI
  44. Cave E, Weinberg MS, Cilliers T, et al.: Silencing of HIV-1 subtype C primary isolates by expressed small hairpin RNAs targeted to gag. AIDS Res Hum Retroviruses 2006, 22:401–410. · DOI
  45. Lee SK, Dykxhoorn DM, Kumar P, et al.: Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood 2005, 106:818–826. · DOI
  46. Sabariegos R, Gimenez-Barcons M, Tapia N, et al.: Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol 2006, 80:571–577. · DOI

Cited by

Sorted by citations

Metadata

Authors
Huang, D. D.
Affiliations
Rush University (US)
Corresponding author
Huang, Diana D.
Venue
Current HIV/AIDS Reports
Publisher
Springer Science and Business Media LLC
Published
2008-02
Volume
5
Issue
1
Pages
33-39
ISSN
  • 1548-3568 (ISSN-L)
  • 1548-3576
DOI
10.1007/s11904-008-0006-4
PMC
PMC7088822
OpenAlex
W1993472529
Cited by
20
References
1
Citations by year
2024: 1 · 2023: 1 · 2022: 2 · 2019: 1 · 2017: 2 · 2015: 1 · 2014: 1 · 2012: 1
FWCI
0.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Current HIV/AIDS Reports (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
RNA interference, antiviral therapy, viral infection, gene silencing, HIV, hepatitis B virus, hepatitis C virus, chronic viral infection, respiratory syncytial virus, nucleic acid therapeutics, clinical trials
MeSH terms
Antiviral Agents, Humans, Proteins, Viral Proteins, Virus Diseases, Viruses, RNA Interference, RNA, Small Interfering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review